A phase I trial of first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers.
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Claudin 18.2 CAR T cell therapy (Primary)
- Indications Gastric cancer; Pancreatic cancer
- Focus Adverse reactions
- 12 Aug 2017 New trial record
- 10 Aug 2017 According to a CARsgen media release, patient recruitment starts at Changhai Hospital of Shanghai. Oncologist Xianbao Zhan, Ph.D & MD,is a principal investigator on this study.